The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 7 May 2026•Updated 7 May 2026•

1 min read

Genmab Q1 Revenue Surges 25% Amid Favorable FDA Regulatory Update

Key Facts

1Total revenues decreased by 8% to US$72.4 million compared to the first quarter of 2025.

2Joenja revenue grew by 34% to US$14.1 million, driven by strong patient uptake.

3The company reaffirmed its total revenue guidance for the full year 2026.

Genmab reported a robust 25% increase in Q1 2026 revenue, reaching $896 million. Alongside financial growth, the company received FDA approval for an sBLA to remove the 24-hour hospitalization recommendation for patients with third-line plus relapsed/refractory DLBCL. The company is actively integrating Merus while maintaining a sharp focus on its late-stage clinical portfolio, which includes EPKINLY, Rina-S, and petosemtamab. These developments highlight Genmab's operational momentum and the improving accessibility of its treatments. Investors are closely monitoring the progress of these late-stage assets as the company seeks to solidify its position in the global biotechnology market.

28 days ago

Version History

Version 128 days ago

What changed: Updated the story to reflect Genmab's Q1 results showing a 25% revenue increase and a new FDA regulatory approval regarding hospitalization requirements for DLBCL patients.